Trial reportNature2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Erratum issuedOpen access · hybridAbstract readClinical Trial
In one paragraph
Trial report in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 126 citations in OpenAlex.
- Trial
- Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Nature medicine · 2024Trial
- 2Journal of enzyme inhibition and medicinal chemistry · 2026Article
- RingKin: portraying the vast macrocyclic chemical universe surrounding kinase drugs.Chemical science · 2026Article
- WDCN: a comprehensive neural network based approach for estimating breast cancer risk.Briefings in bioinformatics · 2026Article
- Identification of novel FGFR2::TXLNB Fusion in a polymorphous low-grade neuroepithelial tumor of the young.Brain pathology (Zurich, Switzerland) · 2026Article
- Review
- Overexpression of FGFR2 in Mandibular Ameloblastoma Is Potentially Associated with Gene Amplification and Deletion.International journal of molecular sciences · 2026Article
- PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.Pathology international · 2026Article
- Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.Nature genetics · 2026Article
- A case of neuroendocrine carcinoma of the urachal cancer with comprehensive genomic profiling results.International cancer conference journal · 2026Article
- FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.Cancers · 2025Review
- Identification and prioritization of high-frequency biomarkers and therapeutic targets in gastric cancer trials.BMC cancer · 2025Article
- Gastrointestinal cancer: molecular pathogenesis and targeted therapy.Molecular biomedicine · 2025Review
- Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.NPJ precision oncology · 2025Article
- Computer-Aided Drug Design Across Breast Cancer Subtypes: Methods, Applications and Translational Outlook.International journal of molecular sciences · 2025Review
- Computational Approaches for Pathway-Centric Analysis of Protein Post-Translational Modifications.Proteomics · 2025Review
- The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer-A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Recurrent FGFR2 and PIK3CA Mutations in Sialoblastoma.Head and neck pathology · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
48 authors at 10 institutions in 3 countries.
Daniel Zingg *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6450-2534
Jinhyuk Bhin *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8898-4531
Julia Yemelyanenko *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-9697-2039
Sjors M Kas *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Frank RolfsDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Catrin LutzDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jessica K LeeFoundation Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4333-5092
Sjoerd KlarenbeekExperimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1891-1940
Ian M SilvermanIncyte Research Institute, Wilmington, DE, USA.ORCID http://orcid.org/0000-0003-3819-6726
Stefano AnnunziatoDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Chang S ChanDepartment of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0001-9897-4759
Sander R PiersmaOncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Timo EijkmanDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Madelon BadouxDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ewa GogolaDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bjørn SiteurMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Justin SprengersMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bim de KleinDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Richard R de Goeij-de HaasOncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Gregory M RiedlingerDepartment of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.
Hua KeDepartment of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Russell MadisonFoundation Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7838-2526
Anne Paulien DrenthDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eline van der BurgDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eva SchutDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Linda HennemanDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Martine H van MiltenburgDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Natalie ProostMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huiling ZhenIncyte, Wilmington, DE, USA.
Ellen WientjensDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Roebi de BruijnDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Julian R de RuiterDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ute BoonDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Renske de Korte-GrimmerinkMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bastiaan van GerwenMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Luis FélizIncyte Biosciences International, Morges, Switzerland.ORCID http://orcid.org/0000-0003-0659-229X
Ghassan K Abou-AlfaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeffrey S RossFoundation Medicine, Cambridge, MA, USA.
Marieke van de VenMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sven RottenbergDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2044-9844
Edwin CuppenOncode Institute, Utrecht, The Netherlands.
Anne Vaslin ChessexDebiopharm International, Lausanne, Switzerland.
Siraj M AliFoundation Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7477-4023
Timothy C BurnIncyte Research Institute, Wilmington, DE, USA.ORCID http://orcid.org/0000-0001-6648-4333
Connie R JimenezOncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Shridar GanesanDepartment of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. ganesash@cinj.rutgers.edu.
Lodewyk F A WesselsOncode Institute, Utrecht, The Netherlands. l.wessels@nki.nl.ORCID http://orcid.org/0000-0002-1656-6995
Jos JonkersDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.ORCID http://orcid.org/0000-0002-9264-9792
The Netherlands Cancer Institute · NLRutgers, The State University of New Jersey · USAmsterdam University Medical Centers · NLFoundation Medicine (United States)Incyte (United States) · USDebiopharm (Switzerland) · CHMemorial Sloan Kettering Cancer Center · USSUNY Upstate Medical University · USUniversity Medical Center Utrecht · NLUniversity of Bern · CH
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA072720Wellcome Trust
Abstract
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer
Indexed as
ExonsGene DeletionMolecular Targeted TherapyNeoplasmsOncogenesProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2AnimalsHumansMiceFGFR2 protein, humanProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.